Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v. grade >= ) that could interfere with study endpoints or put patient safety at risk
Known severe hypersensitivity reactions to monoclonal antibodies; any history of anaphylaxis or uncontrolled asthma.
Known severe (grade >=  NCI-CTCAE) hypersensitivity reactions to monoclonal antibodies, or history of anaphylaxis.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel or avelumab, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade >= )
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version [v] .), any history of anaphylaxis or history of uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] v.), any history of anaphylaxis, or recent (within  months) history of uncontrolled asthma.
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v].)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE v. grade >= )
Patients with a known allergy or hypersensitivity to the protocol therapies or any of their components to be used in the arm the patient is to be enrolled on. Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma).
Known severe (National Cancer Institute [NCI]- Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade  or ) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade ? )
Known prior severe hypersensitivity to investigational product(s) or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v . grade >= ).
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade ? )
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade >= )
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v. grade >= )
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade , any history of anaphylaxis, or uncontrolled asthma
Known severe (grade >=  NCI-CTCAE version [v].) hypersensitivity reactions to monoclonal antibodies, including hypersensitivity to the investigational agent or any component in its formulations, or history of anaphylaxis
Patients with a known allergy or hypersensitivity to avelumab, -azacytidine, or any of their components; known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies (grade >=  National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version [v].), any history of anaphylaxis or uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies (Grade greater than or equal to (>=)  NCI CTCAE v .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
History of severe hypersensitivity reaction to any monoclonal antibody (grade >=  National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade >= )
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade >= )
Known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade ?), any history of anaphylaxis, or uncontrolled asthma (i.e., ? features of partly controlled asthma).
History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >=  NCI CTCAE version [v] .), any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade >= )
Known severe (National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v]. grade  or ) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is,  or more features of partially controlled asthma)
